

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6590593

| | |
|---|-----------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| EVIVE BIOTECHNOLOGY (SHANGHAI) LTD | 03/03/2021 |
| RECEIVING PARTY DATA | |
| Name: | EVIVE BIOTECH LTD. |
| Street Address: | PO BOX 309, UGLAND HOUSE |
| City: | GRAND CAYMAN |
| State/Country: | CAYMAN ISLANDS |
| Postal Code: | KY1-1104 |
| PROPERTY NUMBERS Total: 3 | |
| Property Type | Number |
| Patent Number: | 8846042 |
| Patent Number: | 10870701 |
| Application Number: | 14479203 |
| CORRESPONDENCE DATA | |
| Fax Number: | (650)494-0792 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 6508135736 |
| Email: | drovetti@mofo.com |
| Correspondent Name: | JIAN XIAO |
| Address Line 1: | MORRISON & FOERSTER LLP |
| Address Line 2: | 755 PAGE MILL ROAD |
| Address Line 4: | PALO ALTO, CALIFORNIA 94304 |
| ATTORNEY DOCKET NUMBER: | 72062-20007.00, 7.01, 8.0 |
| NAME OF SUBMITTER: | JIAN XIAO |
| SIGNATURE: | /Jian Xiao/ |
| DATE SIGNED: | 03/09/2021 |
| Total Attachments: 5 | |
| source=Corporate to Corporate Assignment#page1.tif | |
| source=Corporate to Corporate Assignment#page2.tif | |
| source=Corporate to Corporate Assignment#page3.tif | |

source=Corporate to Corporate Assignment#page4.tif
source=Corporate to Corporate Assignment#page5.tif

CORPORATION TO CORPORATION ASSIGNMENT

This Corporation to Corporation Assignment (this "Assignment") is by:

Assignor: **Evive Biotechnology (Shanghai) Ltd**
Address: Floor 3, Building 1, No. 400 Fangchun Road
China (Shanghai) Pilot Free Trade Zone
Shanghai 201207
China

a China corporation

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment or operation of law, of the U.S., foreign and international patent applications and the U.S. and foreign patents identified in the attached **Schedule A** and the inventions covered thereby.

This Assignment is to:

Assignee: **Evive Biotech Ltd.**
Address: PO Box 309, Uglan House
Grand Cayman KY1-1104
Cayman Islands

a Cayman Islands company

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent applications and patents and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

1. Assignor hereby unconditionally and irrevocably assigns, conveys, transfers and sets over, to Assignee and its successors, legal representatives and assigns, Assignor's entire right, title and interest in, to and under the above-mentioned patent applications, patents and inventions, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, national or regional stage entries of said international applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor, thereon or as a result thereof, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceedings, and any and all extensions of said letters patent or patents (collectively, the "Assigned Patents"), and all rights under the Paris Convention for the Protection of Industrial Property and any other applicable law with respect to the Assigned Patents, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said patent applications and patents and any and all patent applications and patents claiming priority thereto or based thereon), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which said letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this Assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this Assignment, Assignor is the sole and lawful owner of the entire right, title and interest in, to and under said patent applications, patents and inventions, that the same are unencumbered, and that Assignor has good and full right and lawful authority to assign, convey, transfer and set over the same in the manner set forth in this Assignment, or (b) that Assignor has assigned, conveyed, transferred and set over, to Assignee and its successors, legal representatives and assigns, the entire right, title and interest in, to and under said patent applications, patents and inventions, that at the time of such assignment, Assignor was the sole and lawful owner of the entire right, title and interest in, to and under said patent applications, patents and inventions, that the same, as and when solely and lawfully owned by Assignor, were unencumbered, and that Assignor had good and full right and lawful authority to assign, convey, transfer and set over the same in the manner set forth in such assignment.

3. Assignor shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, or defense of the Assigned Patents by, or otherwise to secure title thereto to, Assignee and its successors, legal representatives and assigns, at the sole cost and expense of Assignee and its successors, legal representatives and assigns. For purposes of this paragraph, "procurement, maintenance, enforcement, or defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner of Patents in the United States to issue the above mentioned letters patent of the United States to Assignee, and the counterpart thereof in each other applicable country and jurisdiction to issue the above mentioned patents of such other country or jurisdiction to Assignee, in each case as the assignee of said inventions for the sole use of Assignee and its successors, legal representatives and assigns.

5. Assignor hereby grants Assignee's attorneys the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or any foreign patent issuing authority for recordation of this Assignment, including the power to insert on this Assignment the application number and filing date of said applications when known.

6. This Assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one instrument.

[Signature pages follow]

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Evive Biotechnology (Shanghai) Ltd

Date: Mar-3-2021

Signature: _____



Name: **Bo Qi**

Title: **General Manager**


In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

We accept this Assignment:

ASSIGNEE:

Date: 2021.03.04

Evive Biotech Ltd.

Signature: 

Name: **Jubo Liu**
Title: **Director**

SCHEDULE A

| Projects | Invention Title | Priority date | Appln. No. | Appln. date | Patent No. | Issue date | Expiration date | Country | Status | Remark |
|----------|---|---------------|-------------------|-------------|------------------|------------|-----------------|---------|---------|-------------------|
| ITAB | MULTI-SPECIFIC FAB FUSION PROTEINS AND METHODS OF USE | 2011/05/16 | 13/473,017 | 2012/05/16 | 8946042 | 2014/09/30 | 2032/05/16 | US | Granted | PCT/US2012/038177 |
| | | | 14/479,203 | 2014/09/05 | | | | US | Pending | |
| | | | 201280033111.1 | 2012/05/16 | ZL201280033111.1 | 2017/11/03 | 2032/05/16 | CN | Granted | |
| | | | 14111991.0 | 2012/05/16 | 1198540 | 2018/06/08 | 2032/05/16 | HK | Granted | |
| | | | 2014-511496 | 2012/05/16 | 6400470 | 2018/09/14 | 2032/05/16 | JP | Granted | |
| | | | 2018-98731 | 2012/05/16 | | | | JP | Pending | |
| | | | 2021-128 | 2012/05/16 | | | | JP | Pending | |
| | | | 201711214918.6 | 2012/05/16 | | | | CN | Pending | |
| | | | 18107169.0 | 2012/05/16 | | | | HK | Pending | |
| | | | 201711259184.3 | 2012/05/16 | | | | CN | Pending | |
| A-337 | MULTI-SPECIFIC FAB FUSION PROTEINS AND USE THEREOF | 2016/03/15 | 18107170.7 | 2012/05/16 | | | | HK | Pending | PCT/CN2017/076816 |
| | | | 2017233121 | 2017/03/15 | | | | AU | Pending | |
| | | | 3017776 | 2017/03/15 | | | | CA | Pending | |
| | | | 17765847.3 | 2017/03/15 | | | | EP | Pending | |
| | | | 2018-548416 | 2017/03/15 | | | | JP | Pending | |
| | | | 16/085,542 | 2017/03/15 | 10870701 | 2020/12/22 | 2037/09/1 | US | Granted | |
| A-319 | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF | 2018/09/07 | 19123050.7 | 2017/03/15 | | | | HK | Pending | |
| | | | 201780029960.2 | 2017/03/15 | | | | CN | Pending | |
| A-329 | MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF | 2018/12/24 | PCT/CN2019/127433 | 2019/09/06 | | | | PCT | Pending | |

A-1

sf-4391835